In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9%) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45%), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9%) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms / Gugliotta, L.; Iurlo, A.; Gugliotta, G.; Tieghi, A.; Specchia, G.; Gaidano, G.; Scalzulli, P. R.; Rumi, E.; Dragani, A.; Martinelli, V.; Santoro, C.; Randi, M. L.; Tagariello, G.; Candoni, A.; Cattaneo, D.; Ricco, A.; Palmieri, R.; Liberati, M. A.; Langella, M.; Rago, A.; Bergamaschi, M.; Monari, P.; Miglio, R.; Santoro, U.; Cacciola, R.; Rupoli, S.; Mastrullo, L.; Musto, P.; Mazzucconi, M. G.; Vignetti, M.; Cortelezzi, A.; Vianelli, N.; Martino, B.; De Stefano, V.; Passamonti, F.; Vannucchi, A. M.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 46:(2016), pp. 18-25. [10.1016/j.leukres.2016.04.004]

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

Candoni A.;
2016

Abstract

In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombotic and/or cytoreductive treatment in the follow-up may affect the evaluation of the pro-thrombotic weight of the clinical and biological characteristics at diagnosis. In order to avoid this potential confounding effect, we investigated the relationship between prior thrombosis (PrTh: thrombosis occurred before diagnosis and before treatment) and the characteristics at diagnosis in 977 thrombocythemic patients with MPN, reclassified according to the WHO 2008 criteria. PrTh occurred in 194 (19.9%) patients, with similar rates in the different MPNs. In multivariate analysis, PrTh rate was significantly related to minor thrombocytosis (platelets ≤700 × 109/L), leukocytosis (leukocytes >10 × 109/L), higher hematocrit (HCT >45%), JAK2 V617F mutation, older age, and cardiovascular risk factors (CVRFs). The highest PrTh rate (33.9%) was associated with the coexistence of minor thrombocytosis and leukocytosis. Of note, the inverse relationship between PrTh rate and platelet count is consistent with the hemostatic paradox of thrombocytosis. In conclusion, this analysis in MPN patients disclosed the unbiased characteristics at diagnosis with a pro-thrombotic effect. Moreover, it suggests that the optimal control of blood cells counts, and CVRFs might be of utmost importance in the prevention of thrombosis during the follow-up.
2016
46
18
25
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms / Gugliotta, L.; Iurlo, A.; Gugliotta, G.; Tieghi, A.; Specchia, G.; Gaidano, G.; Scalzulli, P. R.; Rumi, E.; Dragani, A.; Martinelli, V.; Santoro, C.; Randi, M. L.; Tagariello, G.; Candoni, A.; Cattaneo, D.; Ricco, A.; Palmieri, R.; Liberati, M. A.; Langella, M.; Rago, A.; Bergamaschi, M.; Monari, P.; Miglio, R.; Santoro, U.; Cacciola, R.; Rupoli, S.; Mastrullo, L.; Musto, P.; Mazzucconi, M. G.; Vignetti, M.; Cortelezzi, A.; Vianelli, N.; Martino, B.; De Stefano, V.; Passamonti, F.; Vannucchi, A. M.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 46:(2016), pp. 18-25. [10.1016/j.leukres.2016.04.004]
Gugliotta, L.; Iurlo, A.; Gugliotta, G.; Tieghi, A.; Specchia, G.; Gaidano, G.; Scalzulli, P. R.; Rumi, E.; Dragani, A.; Martinelli, V.; Santoro, C.; Randi, M. L.; Tagariello, G.; Candoni, A.; Cattaneo, D.; Ricco, A.; Palmieri, R.; Liberati, M. A.; Langella, M.; Rago, A.; Bergamaschi, M.; Monari, P.; Miglio, R.; Santoro, U.; Cacciola, R.; Rupoli, S.; Mastrullo, L.; Musto, P.; Mazzucconi, M. G.; Vignetti, M.; Cortelezzi, A.; Vianelli, N.; Martino, B.; De Stefano, V.; Passamonti, F.; Vannucchi, A. M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294006
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact